Phase 4 N=28 The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading
Attention Deficit/Hyperactivity Disorder
Primary: Gray Oral Reading Rest, Fourth Edition (GORT-4) — 8.27 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=27 Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD
ADHD · Attention Deficit Hyperactivity Disorder
Primary: Go/No-go Task Performance Correct Inhibitions — 91; 89; 94; 92 percentage correct inhibitions
Phase 4 N=65 Bupropion for Smoking Cessation During Pregnancy
Pregnancy Related · Tobacco Use Disorder
Primary: Change in Cigarette Craving and Total Nicotine Withdrawal Symptoms Between Groups During Medication Treatment — 1.50; 2.07; 3.77; 5.35 MNWS Score
Phase 4 N=50 Comparison of Two Techniques of IV Lidocaine on Propofol Injection Pain
Injections, Intravenous
Primary: Patient Expression of Pain — 0.76; 0.04 units on a scale
Phase 4 N=416 Comparative Efficacy of 4 Oral Analgesics
Pain
Primary: Between Group Difference in Change in Numerical Rating Scale (NRS) Pain Scores — 4.4; 3.5; 3.9; 4.3 units on a scale
Phase 4 N=59 Biomarker Assessment of Glutamatergic Target Engagement
Healthy Controls
Primary: Glutamate + Glutamine (Glx) Response — 0.015; 0.007 Glx over creatinine ratio
Phase 4 N=105 Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Patients With On-treatment Gastrointestinal (GI) AEs (SOC GI Disorders) From Baseline to Week 12 — 52.9; 69.8 percentage of participants
Phase 4 N=71 VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Infections, Herpesviridae
Primary: Mean Percent Days of Subclinical Shedding as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for HSV-2 — 1.5; 5.1 Percentage of days — p=<0.001
Phase 4 N=334 Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
Neovascular Age-related Macular Degeneration
Primary: Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12 — 3.3; 1.7 Letters
Phase 4 N=16 Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab
Osteoarthritis of the Knee
Primary: Change in Cellular Infiltrates From Day 0 to Day 28 — 2; 0; 2; 4 Participants
Phase 4 N=37 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
Type 1 Diabetes
Primary: Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1…
Phase 4 N=110 Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
Attention Deficit Hyperactivity Disorder · Dyslexia
Primary: Change From Baseline to Endpoint in Functional Magnetic Resonance Imaging (fMRI) Activation in Participants With Dyslexia Alone (Pseudoword Rhyming and…
Phase 4 N=60 DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
HIV
Primary: Primary Efficacy Endpoint for Virologic Suppression in HIV-infected Subjects — 27; 25 participants
Phase 4 N=67 Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery
Coronary Artery Disease
Primary: Number of Participants With Stress Hyperglycemic Events in the Intensive Care Unit (ICU) — 22; 25 Participants
Phase 4 N=100 Assessing Maternal Post-partum Pain With Suppositories
Pain
Primary: Pain Level Twenty Four Hours After Delivery — 1; 2 units on a scale — p=.35